docetaxel,rucaparib,abiraterone,enzalutamide
pfizer,astellas,clovis oncology
['rucaparib', 'abira', 'brca', 'triton-3', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'docetaxel', 'abiraterone', 'enzalu', 'enzalutamide']
triton-3: rucaparib vs physicians choice (docetaxel, abiraterone, or enzalutamide) in pts with previously treated brca- or atm-mutated mcrpc. rpfs 11.2 vs 6.4 mo; hr=0.5; p&lt;.0001 favoring rucaparib regardless of physician choice treatment #gu23 #parp #mcrpc
CME experts Sara Fagerlie, PhD, CHCP & Mindy Tanzola, PhD have joined forces at Front Row to share the latest heme/onc news with  clinicians and educators